



RNS

Transaction in Own Shares

## Purchase of own shares

### ZYTRONIC PLC

Released 07:00:07 19 May 2022

RNS Number : 0199M  
Zytronic PLC  
19 May 2022

#### Zytronic plc

("Zytronic" or the "Company")

#### Purchase of Own Shares

Further to the confirmation of its intention to implement a share buyback programme, as set out in its announcement on 17 February 2022, the Company announces that it has purchased 100,000 of its ordinary shares of 1 pence each ("Ordinary Shares") at an average price of 163.5 pence per share through Singer Capital Markets. The Ordinary Shares purchased will be cancelled.

#### Aggregated information

Date of purchase	18 May 2022
Number of Ordinary Shares purchased	25,000
Highest price paid per share	163.5p
Lowest price paid per share	163.5p
Volume weighted average price paid	163.5p

#### Transaction details

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market Abuse Regulation) (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018), a detailed breakdown of individual trades is available below:



Number of Ordinary Shares purchased	Transaction price (GBp)	Time of transaction	Trading venue
25,000	163.5p	16:01:23	AIMX

### **Total voting rights**

Following the purchase and cancellation of these Ordinary Shares, the Company's total issued share capital will consist of 10,281,152 Ordinary Shares, each carrying one voting right. The Company does not hold any Ordinary Shares in treasury. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

### **Enquiries:**

Zytronic plc  
Mark Cambridge, Chief Executive  
Claire Smith, Group Finance Director

0191 414 5511

Singer Capital Markets  
(Nominated Adviser and Broker)  
Aubrey Powell, Rachel Hayes, Amanda Gray, Katherine Coppock

020 7496 3000

### **About Zytronic**

Zytronic is a world-renowned developer and manufacturer of a unique range of internationally award winning optically transparent interactive touch sensor overlay products for use with electronic displays in industrial, self-service and public access equipment.

Zytronic's products employ a sensing solution that is readily configurable and embedded in a laminate core that offers significant durability, environmental stability and optical enhancement benefits to system designers specific requirements.

Zytronic has continually developed process and technological know-how and IP since the late 1990's around two sensing methodologies; the first being single touch self-capacitive which Zytronic markets as PCT™ ("Projected Capacitive Technology") and the second being multi-touch, multi-user mutual-capacitive which Zytronic markets as MPCT™ ("Mutual Projected Capacitive Technology"), in which Zytronic holds five granted patents.

Zytronic operates from a single site near Newcastle-upon-Tyne in the United Kingdom. Zytronic is relatively unique in the touch eco-system as it offers a complete one-stop solution from processing internally the form and factor of the glass substrates, assembles their touch overlay products to customers specific requirements, in environmentally controlled cleanrooms and develops the bespoke firmware, software and electronic hardware to link the interactive overlays to customer's integrated systems and products.



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END